 Home > Active Ingredient News > Immunology News > A&R: Tumor necrosis factor inhibitor therapy is associated with a time-shifted delay in radiographic sacroiliitis progression in patients with axial spondyloarthritis

A&R: Tumor necrosis factor inhibitor therapy is associated with a time-shifted delay in radiographic sacroiliitis progression in patients with axial spondyloarthritis

 Last Update: 2022-05-22
 Source: Internet
 Author: User

Tags

oxidation reduction potential

use fluticasone

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE: Over the years , research on structural damage in axial spondyloarthritis (axSpA) has focused on assessing radiographic spinal progression as one of the main determinants of function and spinal mobility

Research on structural injury for many years has focused on assessing radiographic spinal progression as one of the main factors in determining function and spinal mobility

We included patients from the German spondyloarthritis initial cohort who had at least one sacroiliac joint radiograph at baseline and during follow - up

In total, 301 axSpA patients ( 166 non-imaging [nr-axSpA] and 135 radiographic [r-axSpA] ) contributed 737 imaging intervals .

TNFi is associated with a reduction in radiographic sacroiliitis progression in axSpA patients .

Source:

Torgutalp, M.

Torgutalp, M.
, Rios Rodriguez, V.
, Proft, F.
, Protopopov, M.
, Verba, M.
, Rademacher, J.
, Haibel, H.
, Sieper, J.
, Rudwaleit, M.
and Poddubnyy, D.
(2022), Treatment with Tumour Necrosis Factor Inhibitors is Associated with a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients with Axial Spondyloarthritis: 10-year Results from the German Spondyloarthritis Inception Cohort.
Arthritis Rheumatol.
Accepted Author Manuscript.
https:// doi.
org/10.
1002/art.
42144 https://doi.
org/10.
1002/art.
42144

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.